Imaging Endpoints II

Executive Summary

Imaging Endpoints II is a specialized imaging contract research organization (iCRO) exclusively serving oncology clinical trials. Founded in 2005 and headquartered in Scottsdale, Arizona, the company provides scientific expertise and imaging services to design, analyze, and support regulatory submissions for cancer drug development. By optimizing imaging protocols and analyses, Imaging Endpoints helps sponsors demonstrate therapeutic efficacy, playing a critical role in accelerating oncology trials. The company's deep focus on oncology imaging positions it as a key partner for pharmaceutical and biotech firms developing cancer therapies, especially as imaging endpoints become increasingly important for regulatory decisions. With a mission to 'Connect Imaging to the Cure,' the firm has built a reputation for world-class scientific rigor and reliable execution, serving a growing market driven by the rise of targeted therapies and immuno-oncology agents that require nuanced imaging assessments. As a private company, its financials are not publicly disclosed, but its specialized niche and long operating history suggest stable revenue streams and potential for expansion into adjacent therapeutic areas or technological innovations.

Upcoming Catalysts (preview)

• Q4 2026Adoption of AI-enhanced imaging solutions for tumor response assessment75% success
• Q3 2026Major contract win with top-20 pharma for late-stage oncology trial60% success
• Q2 2027Expansion into radiomics and digital pathology services65% success